Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2017 Earnings Presentation
15 slides from Alkem Laboratories's earnings presentation, Nov 11, 2016
Slide 1: Alkem Laboratories Limited Investor Presentation Q2FY17
Alkem Laboratories Limited Investor Presentation Q2FY17 11th November 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Financial Highlights of Q2FY17 (Consolidated)
Key Financial Highlights of Q2FY17 (Consolidated)
Slide 4: Key Financial Highlights – Q2FY17 Consolidated
Key Financial Highlights – Q2FY17 Consolidated All figures in INR mn Total Revenue from Operations India sales 12,258 10,350 16,383 13,820 Q2FY16 Q2FY17 International sales 3,892 3,269 Q2FY16 Q2FY17 Q2FY16 Q2FY17 Highest ever quarterly sales for the Company
Slide 5: Key Financial Highlights – Q2FY17 Consolidated
Key Financial Highlights – Q2FY17 Consolidated All figures in INR mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 9,970 3,105 8,326 2,554 60.2% 60.9% 18.5% 18.9% Q2FY16 Q2FY17 Q2FY16 Q2FY17 PBT (before Minority Interest) PAT (after Minority Interest) 2,828 3,069 2,669 2,797 Q2FY16 Q2FY17 Q
Slide 6: Key Financial Highlights – H1FY17 Consolidated
Key Financial Highlights – H1FY17 Consolidated Particulars (Rs mn) H1FY17 H1FY16 YoY growth Income from Operations 31,192 26,115 19.4% Gross Profit 18,989 15,877 19.6% Gross Profit margin 60.9% 60.8% EBITDA 5,816 4,617 26.0% EBITDA margin 18.6% 17.7% PBT 5,732 4,904 16.9% PBT margin 18.4% 18.8% PAT
Slide 7: India Business – Highest ever quarterly sales
India Business – Highest ever quarterly sales India Business: Q2FY17 Net Sales of Rs.12,258 million (18.4% growth YoY) • India sales contributed 75.9% to total net sales for Q2FY17 • During the quarter Company’s secondary sales1 grew by 22.9% – higher than corresponding IPM growth of 14.5% • The rob
Slide 8: India Business – Market share improvement
India Business – Market share improvement Source: IMS TSA MAT September 2016
Slide 9: Established Therapies – Continued Outperformance
Established Therapies – Continued Outperformance • During the quarter, the Company delivered more than 600bps of outperformance to the market in Anti-Infectives, Gastro-Intestinal and Pain / Analgesic segments • Mega brands registered strong volume led growth despite the regulatory price cuts • Stro
Slide 10: Emerging Therapies – Building on the Base
Emerging Therapies – Building on the Base • Emerging therapies of the company also registered a healthy performance led by strong secondary sales growth in Anti-diabetic (up 27.2% YoY) and Neuro / CNS (up 17.8% YoY) • Company moved up the ranking in the important therapy areas of Anti-diabetic and C
Slide 11: US Business – A steady quarter
US Business – A steady quarter US Business: Q2FY17 Net Sales of Rs.3,023 million (23.9% growth YoY) • US sales contributed 18.7% to total net sales for Q2FY17 • The Company launched 1 new products during the quarter - in-licensed product • In Q2FY17, the Company received one approval, taking the cum
Slide 12: Other International Markets – Looking for depth over breadth
Other International Markets – Looking for depth over breadth Other International Markets : Q2FY17 Net Sales of Rs.869 million (4.7% growth YoY) • Other International sales contributed 5.4% to total net sales for Q2FY17 • The growth was driven by strong underlying demand in key markets such as Austra
Slide 13: Strategy going forward
Strategy going forward 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force productivity th
Slide 14: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 30th September 2016 Non-Institution, 26.07% Promoter & Institution, Promoter Group, 7.04% 66.88% Institution – Mutual Funds, Financial Institutions, Foreign Portfolio Investors, Foreign Institutional Investors, Nationalised and Non-Nationalised
Slide 15: Thank You
———— J < —% Thank You ’ .